タカラバイオ株式会社は、mRNA ワクチン開発用の研究用試薬、「Vaccinia Capping Enzyme」（ワクシニア キャッピング エンザイム ...

SAN DIEGO - TriLink BioTechnologies, a subsidiary of Maravai LifeSciences (NASDAQ: MRVI), has entered into a License and Supply Agreement with Lonza, a key player in the development and manufacturing ...

mRNAワクチン製造プロセス開発に最適な不純物生成を抑制した独自のRNA合成酵素のHigh Qualityグレード品を発売 タカラバイオ株式会社は、mRNAワクチン製造におけるプロセス開発に適したHigh QualityグレードのmRNA製造用酵素「PrimeCap(TM) T7 RNA Polymerase (low dsRNA), HQ ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

SAN DIEGO, Nov. 10, 2025 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a company with proprietary therapeutic manufacturing technologies, today announced the launch of Prima RNApols™ ExTend Cap AU, ...

Primrose Bio, Inc. (Primrose), a company with proprietary therapeutic manufacturing technologies, announced the launch of Prima RNApols ExTend Cap AU, an RNA polymerase engineered to significantly ...

As RNA therapeutics evolve far beyond their vaccine origins, a new generation of scientists and manufacturers is rethinking how to produce these complex medicines safely, efficiently, and at scale.

Singapore, January 12, 2026: Hongene Biotech today announced the receipt of a grant from the Gates Foundation to develop high-quality, affordable, and patent-free cap analogs for use in mRNA vaccine ...

Hongene Biotech, a vertically integrated RNA technology provider, announced the receipt of a grant from the Gates Foundation to develop high-quality, affordable, and patent-free cap analogs for use in ...